Abstract：
Allergic rhinitis (AR) is a common atopic problem in which immune response to the environmental factors leads to clinical symptoms. Helicobacter pylori neutrophil-activating protein (HP-NAP) as a peptide attenuates Th2 response and stimulates Th1 activation and mucus adhesion promoting protein (MapA) as a cell-surface protein binds to mucus. This study evaluated the effect of HP-NAP and MapA conjugated with alumina nanoparticle on AR. HP-NAP and HP-NAP with MapA were conjugated to alumina nanoparticle and two separate nanoparticles were produced. The AR mice were treated with these and HP-NAP in peptide form. The AR symptoms, gene expression of mucus, levels of IL-33 and IL-4, and total and ovalbumin (OVA)-specific IgE levels were evaluated. Nasal rubbing, sneezing, gene expression of mucus, and IL-33 and IL-4 levels, and OVA-specific and total IgE were decreased in three treated groups compared to AR, and there was a significant decrease in the symptoms in AR-H-M-A group (P < 0.05) when compared to the other treated groups. HP-NAP has a controlling effect on AR, and in nanoparticle-conjugated form it can strongly attach to the airway\'s mucus via MapA. Therefore, cooperation of HP-NAP-alumina with MapA can produce an effective and applicable treatment for AR.
摘要：
过敏性鼻炎（AR）是一种常见的特应性问题，其中对环境因素的免疫反应导致临床症状。幽门螺杆菌中性粒细胞激活蛋白（HP-NAP）作为一种肽减弱Th2反应并刺激Th1激活和粘液粘附促进蛋白（MapA），因为细胞表面蛋白与粘液结合。本研究评估了HP-NAP和MapA与氧化铝纳米颗粒缀合对AR的影响。将HP-NAP和具有MapA的HP-NAP与氧化铝纳米颗粒缀合,并且产生两个单独的纳米颗粒。用这些和肽形式的HP-NAP处理AR小鼠。AR症状,粘液的基因表达，评估IL-33和IL-4的水平，以及总和卵清蛋白（OVA）特异性IgE水平。鼻腔摩擦,打喷嚏,粘液的基因表达，以及IL-33和IL-4水平，与AR相比，三个治疗组的OVA特异性和总IgE降低，与其他治疗组相比，AR-H-M-A组的症状显着降低（P<0.05）。HP-NAP对AR有控制作用，以纳米颗粒结合的形式，它可以通过MapA强烈附着在气道的粘液上。因此,HP-NAP-氧化铝与MapA的合作可以为AR提供有效且适用的治疗方法。
